New tip sheet available for the Behavioral Health HEDIS measure: Follow-Up Care for Children Prescribed ADHD Medication (ADD)

Nov. 2022Important Notices
The ADD HEDIS® measure outlines the importance for members 6 to 12 years old who are newly prescribed a medication for ADHD to receive, at minimum, three appointments—an initial appointment with the prescriber and subsequent appointments with the treatment team, including behavioral health treatment providers—within 10 months of starting the new medication. The tip sheet defines the HEDIS measure and offers providers tips to ensure continuity of care for their patients who are prescribed medications for ADHD for the first time. Learn more about the ADD HEDIS measure.

HEDIS®
The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA.

Recent Announcements

Voluntary nationwide recall: Atorvastatin (Alkem – October)

Ascend Laboratories LLC is recalling multiple lots of Atorvastatin Calcium Tablets USP. Atorvastatin is used for the treatment of high cholesterol and to reduce the risk of certain cardiovascular events, such as heart attack and stroke.
Nov. 2025Pharmacy Updates

October 2025 UPMC for You and UPMC Community HealthChoices formulary update

Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.
Oct. 2025Pharmacy Updates

Voluntary nationwide recall: Ocaliva (Intercept – September)

Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).
Oct. 2025Pharmacy Updates